Rezolute, Inc. Files 8-K with Regulatory Updates
Ticker: RZLT · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1509261
| Field | Detail |
|---|---|
| Company | Rezolute, Inc. (RZLT) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financial-reporting
TL;DR
Rezolute filed an 8-K on Jan 7, 2025, with regulatory and financial updates.
AI Summary
Rezolute, Inc. filed an 8-K on January 7, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and headquartered in Redwood City, California.
Why It Matters
This filing provides important updates and disclosures for investors regarding Rezolute, Inc.'s regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- Rezolute, Inc. (company) — Registrant
- AntriaBio, Inc. (company) — Former company name
- January 7, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Redwood City, CA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed as of January 7, 2025.
What is Rezolute, Inc.'s state of incorporation?
Rezolute, Inc. is incorporated in Nevada.
What was Rezolute, Inc. formerly known as?
Rezolute, Inc. was formerly known as AntriaBio, Inc.
Where are Rezolute, Inc.'s principal executive offices located?
Rezolute, Inc.'s principal executive offices are located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-07 16:05:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
Filing Documents
- tm252102d1_8k.htm (8-K) — 26KB
- tm252102d1_ex99-1.htm (EX-99.1) — 18KB
- 0001104659-25-001666.txt ( ) — 219KB
- rzlt-20250107.xsd (EX-101.SCH) — 3KB
- rzlt-20250107_lab.xml (EX-101.LAB) — 33KB
- rzlt-20250107_pre.xml (EX-101.PRE) — 22KB
- tm252102d1_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On January 7, 2025, Rezolute, Inc. issued a press release to announce that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to ersodetug (previously RZ358) for the treatment of hypoglycemia due to congenital hyperinsulinism. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated January 7 , 2025 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: January 7, 2025 By: /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer